mTOR is targeted by everolimus (along other small molecules; approved by FDA in breast cancer treatment) and is also one of the few intracellular proteins targeted by FDA-approved small molecule drugs (along with CDK4/CDK6 and PARP enzyme). Here, CDK4 is linked to breast cancer.